Immunai CTO and Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugs - Ep. 176
NVIDIA AI Podcast
00:00
Machine Learning to Map the Immune System
So how much of the work that immuniis doing is a involves synthetic data, as opposed togess biological data. We really believe that synthetic data would be a big part of the future of the f computational methods,. But right now we actually do not rely very taa on synthetic data. So this is, and the bing reason for that is because i think we leet still much more data and much more understanding around like the biasis. The data to be with wic to generate a trustwor infate. That's what amuno therapy is in the rollin and finding and developing new therapeutics.
Transcript
Play full episode
